In an Era of ctDNA, Is Metabolomics the New Kid on the Block?

Mass action drives the serum homeostasis of metabolites. Recent developments in biofluid metabolomics suggest the potential to harness these changes using small volumes of blood to diagnose, monitor, and risk stratify patients with cancer. This current study may represent a complementary technology to circulating tumor DNA detection. See related article by Larkin et al., p. 1651.